Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
02:35pm, Tuesday, 21'st Jan 2025
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
05:47am, Tuesday, 21'st Jan 2025
Few drugs have generated as much excitement as Novo Nordisk's (NVO -5.27%) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 diabete
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
11:55am, Monday, 20'th Jan 2025
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
Investors who Lost Money on Novo Nordisk A/S Should Contact Levi & Korsinsky About an Ongoing Investigation - NVO
11:00am, Monday, 20'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possi
Novo Nordisk A/S - share repurchase programme
09:32am, Monday, 20'th Jan 2025
Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and C
Is Novo Nordisk Stock a Buy?
05:32am, Saturday, 18'th Jan 2025
It hasn't been a great period for investors in Novo Nordisk (NVO -5.27%) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Its
Dr. Kavita Patel talks impact of GLP-1 price negotiations
06:45pm, Friday, 17'th Jan 2025
Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers.
3-Stock Lunch: Intel, Sherwin-Williams & Novo Nordisk
03:34pm, Friday, 17'th Jan 2025
Gina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks.
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
02:30pm, Friday, 17'th Jan 2025
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's
Ozempic, Wegovy among drugs subject to Medicare price controls
11:55am, Friday, 17'th Jan 2025
The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
11:37am, Friday, 17'th Jan 2025
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treatin
Novo Nordisk shares fall after Ozempic, Wegovy selected for Medicare price negotiations
11:19am, Friday, 17'th Jan 2025
Novo Nordisk (NYSE:NVO) shares plummeted after the US Medicare program announced it plans to include the firm's weight loss medications in its second round of price negotiations. Shares of the Danish
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
08:23am, Friday, 17'th Jan 2025
Analysts at Argus Research say the stock is now trading at 22 times its estimated 2025 earnings.
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
08:05am, Friday, 17'th Jan 2025
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.
Novo Nordisk says high-dose semaglutide trial shows 20.7% weight loss
07:22am, Friday, 17'th Jan 2025
Novo Nordisk said on Friday that a late-stage trial with 7.2 milligram (mg) of semaglutide, a high-dose version of the active ingredient used in its blockbuster obesity drug Wegovy, helped overweight
